­

News: Gene therapy to cure leukemia at one-tenth global costs in the works

­

ImmunoACT, an IIT-Bombay spin-off backed by Hyderabad-based Laurus Labs, is testing a new gene-therapy treatment for cancer, which they claim would not only cure the disease, but also costs one-tenth of the global price. “We are working with CD19 CAR T Cell for leukemia and lymphoma. What we do is we take out some blood and plasma from the cancer patient, and then isolate the T-cells (which are immune cells) from this sample. These cells are then genetically modified so that they eliminate cancer cells. Then this is transfused back to the patient,” explains Rahul Purwar, founder and chairman of ImmunoACT. The product is named H-CAR T-19. 

Read more…

­

­

News: Gene Therapy Successfully Treats Spinal Cord Injuries Without Side Effects

­

In mouse studies, pain-blocking neurotransmitters produced long-lasting benefits without detectable side effects. An international team of researchers led by scientists at the University of California San Diego School of Medicine reported that a gene therapy that inhibits targeted nerve cell signaling effectively reduced neuropathic pain in mice with spinal cord or peripheral nerve injuries with no detectable side effects.

Read more…

­

­

Conference: World Orphan Drug Congress USA

­

The World’s Most Important Orphan Drug and Rare Disease Event is coming to Boston, MA this July 11-13th! The World Orphan Drug Congress brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies.
Join us for three days in Boston for the most comprehensive program and inclusive gathering of rare disease stakeholders. Enjoy an exclusive 50% discount when you register with code GENE50.

Register now…

­

­

Conference: In Vivo Engineering of Therapeutic Cells Summit

­

In vivo gene engineering is fast becoming known as the future of cell and gene therapy with incredible amounts of investment in 2021, including the Moderna and Metagenomi collaboration alongside the partnership between Abintus Bio and MSKCC, and Tidal’s acquisition by Sanofi.
This game-changing approach promises to replace current ex vivo cell and gene therapies due to their potential ability to directly engineer target cells and remove the need for costly and labor-intensive manufacturing processes.
Join the In Vivo Engineering of Therapeutic Cells Summit, July 11-13th,  to be brought up to speed on the revolutionary advances in payload delivery in cell and gene therapy. Learn from industry pioneers from Sana Biotechnology, Umoja Biopharma, Beam Therapeutics and Capstan Therapeutics to improve efficacy by reaching a significant number of target cells – including immune cells, liver cells and hematopoietic stem cells, ensuring tolerability for safe dosing strategies, and the considerations for the most optimal in vivo delivery modality comparing viral vectors, mRNA, or non-viral LNPs.
Register now…

­

­

Conference: 2nd Annual Next Generation Gene Therapy Vectors Summit 

­

This July, industry pioneers from cutting edge biopharma and world-leading academic vectorology groups including Voyager Therapeutics, Spark Therapeutics, Dyno Therapeutics, Chameleon Biosciences, BioMarin and more will be joining at the 2nd Annual Next Generation Gene Therapy Vectors Summit,July 18-20, 2022, to share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach.
Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before
Register now…

­

­

Conference: 3rd Gamma Delta T Therapies Summit

­

Recent headlines tout 2022 as the year for γδT-based therapies, as they’ve started to show significant clinical benefit. With such momentum in the field, the 3rd Gamma Delta T Therapies Summit (July 26-28, 2022 | Boston, MA) is your opportunity to advance bench to commercial bedside development of γδT-based therapies.

Take a look at the official program here with world-class speaker faculty including Adrian Hayday, a pioneer of the field. Enhance cytotoxicity, discover novel targets, engineer stealth and persistence, interrogate cell subsets, and scale-up manufacturing through a deep understanding of the fundamental biology and target product profile for γδT therapies.

Industry experts agree that this year, the γδT is the cell to know. Join 120+ industry leaders including Adicet Bio, TC Biopharm, GammaDelta Therapeutics, ImCheck Pharmaceuticals, Lava Therapeutics, and more, who will be gathering to discuss discovery to manufacturing and clinical development of these ‘holy grail’ therapies in allogeneic and solid tumor settings.
Register now…

­

­

Conference: 2nd Annual mRNA-Based Therapeutics Summit

­

The 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28.
Expect exclusive data from the movers and shakers in mRNA vaccine and therapy development, 75+ world-class speakers, 5 dedicated tracks of content and 45+ deep-dive case studies. Find out more in the full event guide: https://ter.li/lbiwdy

Download the official brochure to discover why Sanofi, Ultragenyx, Beam Therapeutics, Pfizer, Moderna, Merck, Eli Lilly, GSK, and many others have already secured their places. 
Register now…

­

­

Conference: Cell Therapy Durability Response Summit

­

The inaugural Cell Therapy Durability Response Summit is the only industry networking forum dedicated to the #1 challenge of the field: durability.

The summit will be held in Boston, Massachusetts from 22-23 August and there are over 23 speakers confirmed to give talks at the event. Speakers come from companies including Abbvie, Editas Medicine, Be Bipharma and many more! These talks will cover:

- Target Selection and receptor design
- Enhancing activity and persistence in the immunosuppressive tumor microenvironment
- Genetic Engineering and synthetic biology
- Moving beyond CAR-αβT and CAR-NK cells to generate durable responses

You can expect to meet researchers from cell therapy biotechs, representatives from pharmaceutical companies in the cell therapy space, academic experts and R&D solution providers, giving you the perfect chance to speak with experts in the industry. 
Register now…

­

­

Upcoming conferences and meetings

­

• 20 - 23 June 2022 - 2nd Inner Ear Disorders Therapeutics Summit - Gene Therapies - Boston, MA
• 22 - 23 June 2022 - Rare & Genetic Neurodegenerative Drug Development Summit - Gene Therapies - Boston, MA
• 27 - 28 June 2022 - Cell Therapy at the Limits - London, UK
• 27 - 29 June 2022 - 3rd TCR-based Therapies for Solid Tumors Summit - Boston, MA
• 29 - 30 June 2022 - Onco Cell Therapy Summit (OCTS) - Boston, MA
• 11 - 13 July 2022 - 3rd Annual Gene Therapy for Neurological Disorders Europe - Paris, France
• 11 - 13 July 2022 - World Orphan Drug Congress USA 2022 - Boston, MA
• 12 - 14 July 2022 - In Vivo Engineering of Therapeutic Cells Summit - Boston, MA
• 12 - 14 July 2022 - BCMA Targeted Therapies - CAR-modified T-cell therapy - Boston, MA
• 18 - 20 July 2022 - 2nd Annual Next Generation Gene Therapy Vectors Summit - Boston, MA
• 26 - 28 July 2022 - 3rd Gamma Delta T Therapies Summit - Boston, MA
• 26 - 28 July 2022 - 2nd Annual mRNA-Based Therapeutics Summit - Boston, MA
• 26 - 28 July 2022 - iPSC Manufacturing Summit - Gene and Cell therapies - Boston, MA
• 15 - 18 August 2022 - Bioprocessing Summit - Gene and Cell therapies - Boston, MA
• 22 - 23 August 2022 - The Cell Therapy Durability Response Summit - Boston, MA
• 24 - 25 August 2022 - Vector Development for Cell and Gene Therapy Summit - Boston, MA
• 6 - 8 September 2022 - Optimizing AAV Safety Summit - Boston, MA
• 13 - 16 September 2022 - 3rd Annual Gene Therapy for Ophthalmic Disorders - Boston, MA
• 19 - 23 September 2022 - 7th Annual CAR-TCR Summit - Boston, MA
• 20 - 21 September 2022 - Cell & Gene Therapy USA 2022 - Online event
• 20 - 22 September 2022 - mRNA Process Development & Manufacturing Summit - Boston, MA
• 21 - 22 September 2022 - Oligonucleotide Therapeutics and Delivery 2022 - London, UK
• 26 - 28 September 2022 - International Human Gene Therapy Conference - Melbourne, Australia
• 27 - 30 September 2022 - Cell & Gene Therapy Manufacturing & Commercialization US - Boston, MA & Online
• 11 – 14 October 2022 - XXIX Congress of the European Society of Gene and Cell Therapy (ESGCT) - Edinburgh, UK
• 13 - 14 October 2022 - Global Bioprocessing Summit and Expo - ATMP Development - Berlin, Germany
• 24 - 26 October 2022 - 4th TIL Therapies Summit - Boston, MA
• 7 – 8 November 2022 - 8th Annual Cell & Gene Therapy Manufacturing Congress - London, UK
• 16 – 18 November 2022 - Joint meeting of the Australasian Gene and Cell Therapy Society - Melbourne, Australia
• 5 - 8 December 2022 - Cell & Gene Therapy Manufacturing & Commercialization Europe - Amsterdam & Online

­